Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer

Mangir N., Turkeri L.

ACTAS UROLOGICAS ESPANOLAS, cilt.38, sa.8, ss.515-522, 2014 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 8
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.acuro.2013.12.012
  • Dergi Adı: ACTAS UROLOGICAS ESPANOLAS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.515-522
  • Anahtar Kelimeler: Prostate cancer, Castration resistant, Chemotherapy, Docetaxel, Toxicity, Survival, MITOXANTRONE PLUS PREDNISONE, ELDERLY-PATIENTS, CLINICAL-TRIALS, OLDER, AGE, PARTICIPATION
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Introduction: Docetaxel administered every 3-weeks is the standart treatment of castration resistant prostate cancer (CRPC) but it is associated with dose limiting toxicities. We analyzed the efficacy and tolerability of 3- weekly and weekly docetaxel in a Turkish cohort of CRPC patients with a special emphasis on the elderly patients.